Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium

Trial Profile

Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Glatiramer acetate (Primary) ; Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BECOME
  • Most Recent Events

    • 10 Sep 2009 Results were presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), according to a Bayer Schering Pharma media release.
    • 20 Sep 2008 Results presenetd at ECTRIMS/ACTRIMS/LACTRIMS
    • 08 Nov 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top